Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

Trial Details

NCT ID
NCT04363164
Phase
PHASE2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • Testosterone cypionate
  • Enzalutamide
  • Testosterone enanthate
Locations (sample)
  • San Diego, California, United States|32.71571,-117.16472
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • ECOG Performance status ≤2.
  • Age ≥18 years.
  • Histologically-confirmed adenocarcinoma of the prostate.
  • Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →